ImmunityBio, Inc. (IBRX) Stock Analysis

Q: What is the IBRX stock price target?

Take-profit $12.88 (+80.9% upside). Prior stop was $6.62.

Q: What are the risks of investing in IBRX?

Negative momentum; Elevated risk factors; Value-trap signals (3/5): Margin compression (op margin -169.0%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow; Momentum score 2.7/10 — below 4.5 minimum.

Q: Is IBRX overvalued or undervalued?

ImmunityBio, Inc. trades at a P/E of N/A (forward -348.0). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about IBRX?

11 analysts cover IBRX with a consensus score of 4.3/5. Average price target: $15.

Range Bound setup

SellVALUE-TRAP 3/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

$7.12+80.9% A.UpsideScore 5.5/10#40 of 158 Biotechnology

Stop $6.62Target $12.88(analyst − 13%)A.R:R 5.6:1

Analyst target$14.80+107.9%5 analysts

$12.88our TP

$7.12price

$14.80mean

$23

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $7.12 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Elevated risk factors. Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.

Thesis

Rewards

Attractive valuation

Analyst upside: 81%

Risks

Negative momentum

Elevated risk factors

Value-trap signals (3/5): Margin compression (op margin -169.0%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—

P/E (Fwd)-348.0

Mkt Cap$7.2B

EV/EBITDA-32.2

Profit Mgn0.0%

ROE—

Rev Growth407.0%

Beta0.06

DividendNone

Rating analysts11

Quality Signals

Piotroski F5/9

Options Flow

P/C0.75neutral

IV119%elevated

Max Pain$1-93.0% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality4.815%0.72

Growth5.015%0.75

Momentum2.710%0.27

Sentiment7.610%0.76

Insider Activity3.910%0.39

Peer Rank5.010%0.50

Technical Setup5.45%0.27

Risk Profile3.65%0.18

Catalyst7.55%0.38

Overall (Σ contributions)5.56

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Obv

1.0

Macd

2.8

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.7<4.5EARNINGS PROXIMITY 11d<=14d (soft)A.R:R 5.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate

RSI

48 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $6.68Resistance $8.56

Price Targets

$13

A.Upside+80.9%

A.R:R5.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Momentum score 2.7/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-05-11 (11d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is IBRX stock a buy right now?

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $7.12 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Elevated risk factors. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $6.62. Score 5.5/10, moderate confidence.

What is the IBRX stock price target?

Take-profit target: $12.88 (+80.9% upside). Prior stop was $6.62. Stop-loss: $6.62.

What are the risks of investing in IBRX?

Negative momentum; Elevated risk factors; Value-trap signals (3/5): Margin compression (op margin -169.0%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow.

Is IBRX overvalued or undervalued?

ImmunityBio, Inc. trades at a P/E of N/A (forward -348.0). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about IBRX?

11 analysts cover IBRX with a consensus score of 4.3/5. Average price target: $15.

What does ImmunityBio, Inc. do?ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation...

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.